Drugs / Mirvetuximab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05483933 | Aug 2022 → Feb 2025 | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma, refractory malignant neoplasm | Shattuck Labs, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-08-01 | Shattuck Labs, Inc. | Results Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights shattucklabs.com ↗
As of the April 23, 2024 data cutoff, ORR benefit beyond Elahere alone was not observed. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-01 | Shattuck Labs, Inc. | Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights shattucklabs.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mirvetuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483933 ↗ |
| Known as | M-9346A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545192 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3545192 ↗ |
| Route | Intravenous | “Mirvetuximab (MIRV) will be administered via intravenous administration” NCT05483933 ↗ |
| Target | FOLR1 | “Folate receptor alpha binding agent” CHEMBL3545192 ↗ |